Alvine Hopes To Bring The First Celiac Drug To Market With New Partner AbbVie
This article was originally published in The Pink Sheet Daily
Alvine and AbbVie have inked a deal that could allow the larger company to acquire the biotech based on results of a Phase IIb trial for its celiac disease treatment.
You may also be interested in...
Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.